ACTRN12612001035819招募中2 期
The Effect of Prolonged Glucagon-like Peptide 1 Infusion on Gastric Emptying in Healthy Volunteers
Mahesh Umapathysivam0 个研究点目标入组 10 人开始时间: 2012年9月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 35 Years（—）
- 性别
- All
入选标准
- •2.Normal gastric functioning
排除标准
- •- Inability to give informed consent,
- •- Radiation exposure for research purposes in the past 12 months,
- •- The ARPANSA guidelines published by the Australian Government entitled Code of Practice Exposure of Humans to Ionizing Radiation for Research Purposes States that the dose constraints for a research participant is 5mSv per year and 10mSv for a 5 year period.
- •- History of diabetes,
- •- HbA1c >6.0,
- •- Taking medication that are known to effect gastrointestinal motility,
- •- Taking medication effecting blood glucose,
- •- Creatinine Clearance <100 ml/min (men), 90 ml/min (women)
- •- Pregnancy,
- •- Ferritin level < 20microg/L
- •- Previous surgery on the small intestine,
- •- Smoking >10 cigarettes per day
- •- Alcohol >20g per day
- •- Because of concerns of cumulative life time exposure to radiation, we will directly screen all volunteers as to their previous radiation exposure, and will exclude any volunteer who has received 3 or more examinations using a computerized tomogram and/or 10 or more examinations using standard x-rays.
研究者
相似试验
已完成
2 期
Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?Blood GlucoseType-2 DiabetesMetabolic and Endocrine - DiabetesACTRN12610000185066Adam Deane10
已完成
2 期
Exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in the critically ill.Blood GlucoseMetabolic and Endocrine - Other metabolic disordersACTRN12609000093280Adam Deane8
进行中（未招募）
1 期
iraglutide to Short Bowel Syndrome, a cross-over studyShort bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytesrestricted oral/enteral nutrition to reduce intestinal lossesdisease-related hypophagialack of adaptive hyperphagiaaccelerated gastrointestinal transit timeMedDRA version: 19.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-000825-35-DKRigshospitalet Blegdamsvej16
已完成
1 期
The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.ACTRN12608000428369Royal Adelaide Hospital24
已完成
2 期
Effects of Glucagon-Like Peptide-1 (GLP-1) administration on gastric emptying during periods of hyperglycaemia in healthy volunteers.Glycaemic control and gastric emptyingMetabolic and Endocrine - Other metabolic disordersACTRN12613001384741Dr Mark Plummer15